Tagged with

Generic Medicines Industry Association (GMiA) In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We have been focusing on several strategic priorities over the past four years, firstly on creating a viable commercial environment for…

Biogen Idec Czech Republic Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology, with a specialization in microbiology. I worked for approximately three years doing clinical work in this field at a hospital,…

The Singapore Economic Development Board (EDB) Singapore is widely known as a key regional and global hub for companies to do business in. This reputation would not have been possible without the extensive work of the government. What have been the main driving forces that have allowed this agency to be at the forefront of effectively…

Beacons pharmaceuticals As one of the few surviving Singaporean manufactures, what has been the key to success? Our history spans more than 40 years and our success lies in our ability to manage costs. Furthermore, over the years we have managed to establish a strong brand and earned the reputation of quality…

Maccine Which previous professional experiences have led you to join Maccine? Getting my own company to go public in 2006 in Canada was a success for me; the company had grown quickly to 425 employees and we had 4 facilities around the globe: San Diego, Montreal, Denmark and Hungary. At that…

Mr. De Cuyper, can you start with a brief introduction to the federal agency for medicines and health products (famhp) and its role within the Belgium’s complex regulatory environment? We are the regulatory authority for medicines as well as for medical devices in Belgium. Although many of our counterparts across…

Pronaos Dr. Sommermeyer, you’ve spent approximately two decades working for pharmaceutical companies throughout Europe. From a personal standpoint, why did you decide to leave the industry and found a consultancy? I started my career in research, and then moved to marketing and strategic planning. After ten years spent in headquarter functions,…

CEEROR Mr. Tichopad, can you please begin by introducing yourself and your company to our readers? My background is in bio-statistics. I am a biologist by education, and in the beginning of my career I worked in contract research for pharmaceutical companies as a statistician. Subsequently, I became a health economics…

Lonza Czech Republic Mr. Kužela, you have a very interesting background: from 1993 until 2011, you variously worked for the Staropramen beer factory and its parent organization, StarBev. You identify yourself as an experienced professional in managing the supply chain of FMCG products. How did you come to manage a biotechnology business, and…

CMS Cameron McKenna Czech Republic Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated pharmaceutical regulatory frameworks in Europe–ensuring, for instance, that market access for drugs can take up to three years longer in…

CEPHA Today, the Czech Republic is widely recognized as a major regional hub for clinical development. How would you compare the current environment to the realities of 1992, when CEPHA was first established, and how has CEPHA developed in the ensuing period? The Czech Republic has a long tradition of clinical…

Ms. Polekova, you established the Celgene affiliate in this country from scratch in 2008. When we spoke to Mr. Victor Ferkovich, your colleague in Russia, he commented on his own experience starting the Russia affiliate: ‘The Celgene office was then one room, of about 14 square metersóI only had a…